• About Us
  • Our Editorial Policy
  • Business Directory
  • Advertise with Us
  • Our Advertisers
  • Contact Us
Australia India News
  • Alluring India - Brisbane Banner
India News Australia
  • Home
  • Current Issue
    Past Issue
  • India News
  • Politics
  • Business
  • World
    World This Week
  • Community News
  • What's On
  • Others
    Yoga in Australia News COVID-19 Community News Naari IPL News Health Travel Entertainment
  • Migrants Expo
  • National Events
  • Please wait..
India News News

WHO flags three contaminated cough syrups in India, including Coldrif

  • BY India News Newsdesk
  • October 14, 2025
  • 0 COMMENTS

New Delhi, Oct 14 (IANS) The World Health Organisation (WHO) has identified three adulterated syrups manufactured in India, including the infamous Coldrif cough syrup, and has urged authorities worldwide to report to the agency if any of these products are detected in their respective countries.

The development comes weeks after the deaths of several children in Madhya Pradesh, linked to the consumption of adulterated cough syrup.

Among the three contaminated syrups flagged by WHO is Coldrif, which recently triggered widespread outrage following the children’s deaths.

The global health body has identified specific batches of Coldrif from Sresan Pharmaceuticals, Respifresh TR from Rednex Pharmaceuticals, and ReLife from Shape Pharma as the affected medicines.

WHO warned that the identified syrups could cause severe and potentially life-threatening illnesses.

The Coldrif syrup, manufactured in Tamil Nadu, sparked major alarm after it was found to be dangerously contaminated with the toxic chemical diethylene glycol (DEG).

Tests revealed DEG concentrations exceeding 48 per cent — an alarming figure far above the permissible limit of 0.1 per cent.

Following this, Sresan Pharmaceuticals had its manufacturing license revoked, and its owner, G. Ranganathan, was arrested.

The authorities also ordered a comprehensive inspection of other drug manufacturing companies across the southern state to identify potential lapses in quality control.

The deaths of children in Madhya Pradesh prompted the Central government to issue an advisory to all states and union territories, urging extreme caution in the prescription of cough syrups for children.

The advisory specifically stated that such medications should not be prescribed or dispensed to children below two years of age and are generally not recommended for those under five.

Health officials have emphasised that the incident highlights the urgent need for stricter regulatory oversight of pharmaceutical manufacturing in the country to prevent similar tragedies.

–IANS

sd/dpb

Post navigation

After delays, TNUHDB to inaugurate 1,152-flat housing project in Tiruvallur by Dec
South Korea’s ICT exports surge 14 pc in September on record semiconductor shipments

Related Post

SIT intensifies probe into Ram Janmabhoomi donation fund irregularities
June 16, 2026
SIT intensifies probe into Ram Janmabhoomi donation fund irregularities
June 16, 2026
Odisha: Man arrested for duping job seekers of Rs 43 lakh
June 16, 2026
Amit Malviya flags Akal Takht’s rebuke of Punjab CM Mann
June 16, 2026

Our Current Issue

Alluring India 2026

Alluring India 2026

Our Advertisers

  • Battery Rebate australia
  • Bess Australia Solar Panels
  • Alluring India - Brisbane 2026

Follow Us

  • facebook
  • facebook
  • facebook
  • facebook
INDIA NEWS on YouTube in Australia, bring to our readers and subscribers national and international news, editorials, expert columns, community activities and interviews of political leaders, celebrities, business professionals, academics and sport personalities among others.
  • facebook
  • facebook
  • facebook
  • facebook

Category

  • Accident
  • Adani Australia
  • Advertorial
  • Arts & Culture
  • Ashes 2022
  • Australia

Recent News

  • FIFA WC 2026: Ashour strikes, Hany own...
  • Jharkhand T20 League: Ranchi Titans, Chota Nagpur...

Subscribe Newsletter

Get the latest creative news from india news

  • Privacy Policy
  • Disclaimer